IP Library › Granted Patent US 9,833,469
Granted Patent B2
US 9,833,469 · App. 15/387,138 · Granted Dec 5, 2017

Compositions and methods to affect skin irritation

Inventors: Ronald E. Utecht (Volga, SD); Therese M. Downey (Sioux Falls, SD); Miri Seiberg (Princton, NJ); Stanley S. Shapiro (Roseland, NJ)
Assignees: Alumend, LLC; WavePharma, LLC
A61K31/737A61F13/8405A61K8/347A61K8/736A61K9/0014A61K31/05A61Q19/08A61K2800/75A61K2800/782
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,833,469
App. No.
15/387,138
Granted
Dec 5, 2017
Kind
B2
Abstract

Compositions are described that contain treated chitosan, modified chitosan and/or modified and treated chitosan for use in formulations for skin, hair and nails, and in compositions and methods of reducing topical agent-induced skin irritation and inflammation.

Claims (8)

1. A composition comprising:

(a) at least one topical irritating agent comprising a retinoid, a retinoid derivative, or a retinoid precursor, wherein the retinoid, retinoid derivative and the retinoid precursor are selected from the group consisting of retinol, retinal, retinyl esters, tretinoin, retinoic acid, Vitamin A, ester of Vitamin A, isotretinoin, alitretinoin, etretinate, acitretin, adapalene, bexarotene, and tazarotene, and combinations thereof, and

(b) at least one chitosan covalently modified with octane sulfonic acid via sulfonamide linkage, and

wherein the composition provides a reduction in skin irritation and/or a reduction in skin inflammation and/or a reduction in irritant-induced IL-1α secretion after contact with the composition compared with a control composition comprising the topical irritating agent but not the chitosan.

2. The composition of claim 1 , wherein said retinoid, retinoid precursor or retinoid derivative comprises retinol.

3. The composition of claim 1 , wherein said retinoid, retinoid precursor or retinoid derivative comprises about 0.001-5% W/V of the total weight of the composition.

4. The composition of claim 1 , wherein said at least one chitosan covalently modified with octane sulfonic acid comprises about 0.0001-5% W/V of the total weight of the composition.

5. The composition of claim 1 , wherein the ester of Vitamin A is retinol-palmitate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2017
From: SEIBERG, MIRI; SHAPIRO, STANLEY S
To: WAVEPHARMA, LLC
Reel/Frame 044351/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2017
From: DOWNEY, THERESE M; UTECHT, RONALD E
To: ALUMEND, LLC
Reel/Frame 044680/0579 →
Continuity (2)
Provisional Application 62271591 · Dec 28, 2015
Related Publication 20170182086A1 · Jun 29, 2017